Propofol-based total intravenous anesthesia — Competitive Intelligence Brief

Propofol-based total intravenous anesthesia (Propofol-based total intravenous anesthesia) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GABA_A receptor agonist. Area: Anesthesiology.

phase 3 GABA_A receptor agonist GABA_A receptor Anesthesiology Small molecule

Target snapshot

Propofol-based total intravenous anesthesia (Propofol-based total intravenous anesthesia) — The Cleveland Clinic. Propofol acts as a non-selective GABA_A receptor agonist, enhancing the inhibitory effects of GABA to induce sedation and anesthesia.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Propofol-based total intravenous anesthesia TARGET	Propofol-based total intravenous anesthesia	The Cleveland Clinic	phase 3	GABA_A receptor agonist	GABA_A receptor
Remifentanil and/or propofol	Remifentanil and/or propofol	Alder Hey Children's NHS Foundation Trust	phase 3	Opioid analgesic, Sedative-hypnotic	Opioid receptors, GABA_A receptor
intravenous sedation with propofol	intravenous sedation with propofol	University Hospital, Clermont-Ferrand	phase 3	GABA_A receptor agonist	GABA_A receptor
Sevoflurane, Sufentanil	Sevoflurane, Sufentanil	University of Saskatchewan	phase 3	General anesthetic, Opioid analgesic	GABA_A receptor, Mu-opioid receptor
Propofol induced sedation	Propofol induced sedation	Centre Hospitalier Universitaire de Saint Etienne	phase 3	GABA_A receptor agonist	GABA_A receptor
SAGE-547	SAGE-547	Supernus Pharmaceuticals, Inc.	phase 3	antisense oligonucleotide	GABA_A receptor alpha 1 subunit
topiramate, propranolol	topiramate, propranolol	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	Anticonvulsant	Voltage-dependent sodium channels, GABA_A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GABA_A receptor agonist class)

1. Alkermes, Inc. · 1 drug in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
4. The Cleveland Clinic · 1 drug in this class
5. University Hospital, Clermont-Ferrand · 1 drug in this class
6. Xiaobo Yang, MD · 1 drug in this class